Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries

IF 7.1 1区 医学 Q1 ONCOLOGY European Journal of Cancer Pub Date : 2025-02-25 Epub Date: 2025-01-13 DOI:10.1016/j.ejca.2024.115213
V. Di Carlo , A. Eberle , C. Stiller , D. Bennett , A. Katalinic , R. Marcos-Gragera , F. Girardi , S. Larønningen , A. Schultz , CA. Lima , MP. Coleman , C. Allemani , CONCORD Working Group
{"title":"Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries","authors":"V. Di Carlo ,&nbsp;A. Eberle ,&nbsp;C. Stiller ,&nbsp;D. Bennett ,&nbsp;A. Katalinic ,&nbsp;R. Marcos-Gragera ,&nbsp;F. Girardi ,&nbsp;S. Larønningen ,&nbsp;A. Schultz ,&nbsp;CA. Lima ,&nbsp;MP. Coleman ,&nbsp;C. Allemani ,&nbsp;CONCORD Working Group","doi":"10.1016/j.ejca.2024.115213","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000–2014. Studies showed a survival advantage in women, but the reasons are not completely understood. We aim to estimate trends in age-standardised 5-year net survival by sex and to examine the role of age, anatomic location and stage on the survival advantage for women worldwide.</div></div><div><h3>Methods</h3><div>Patients were grouped into five anatomic locations (head and neck, trunk, limbs, genital organs and not otherwise specified locations), into five age groups (15–29, 30–44, 45–59, 60–74 and 75–99 years) and into binary stage (non-metastatic <em>vs.</em> metastatic).</div><div>We estimated net survival with the non-parametric Pohar Perme estimator, correcting for background mortality by single-year of age, sex, race/ethnicity where possible and calendar year in each country. All-ages estimates were standardised with the International Cancer Survival Standard weights.</div></div><div><h3>Results</h3><div>Men were generally older and with higher proportion of metastatic melanomas than women. Overall, the trunk was the most common location in men (range 31 %-58 %) and the lower limbs and hips in women (26 %-40 %).</div><div>Age-standardised 5-year net survival was lower in men (43 %-92 %) than in women (54 %-95 %) in all countries during 2010–2014 and it was lower at older ages for both sexes. A survival advantage for women was observed for all anatomic sites and for localised disease.</div></div><div><h3>Conclusions</h3><div>Women had a more favourable distribution of main prognostic factors, and showed highest survival for any prognostic factor.</div><div>Public health efforts should focus on raising awareness of early signs of melanoma, especially among elderly in South-East Europe and to increase awareness in East-Asia, where survival was poorest.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"217 ","pages":"Article 115213"},"PeriodicalIF":7.1000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924018203","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000–2014. Studies showed a survival advantage in women, but the reasons are not completely understood. We aim to estimate trends in age-standardised 5-year net survival by sex and to examine the role of age, anatomic location and stage on the survival advantage for women worldwide.

Methods

Patients were grouped into five anatomic locations (head and neck, trunk, limbs, genital organs and not otherwise specified locations), into five age groups (15–29, 30–44, 45–59, 60–74 and 75–99 years) and into binary stage (non-metastatic vs. metastatic).
We estimated net survival with the non-parametric Pohar Perme estimator, correcting for background mortality by single-year of age, sex, race/ethnicity where possible and calendar year in each country. All-ages estimates were standardised with the International Cancer Survival Standard weights.

Results

Men were generally older and with higher proportion of metastatic melanomas than women. Overall, the trunk was the most common location in men (range 31 %-58 %) and the lower limbs and hips in women (26 %-40 %).
Age-standardised 5-year net survival was lower in men (43 %-92 %) than in women (54 %-95 %) in all countries during 2010–2014 and it was lower at older ages for both sexes. A survival advantage for women was observed for all anatomic sites and for localised disease.

Conclusions

Women had a more favourable distribution of main prognostic factors, and showed highest survival for any prognostic factor.
Public health efforts should focus on raising awareness of early signs of melanoma, especially among elderly in South-East Europe and to increase awareness in East-Asia, where survival was poorest.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
皮肤黑色素瘤存活率的性别差异:年龄、解剖位置和诊断阶段的作用:一项在59个国家进行的CONCORD-3研究
背景:CONCORD-3强调了2000-2014年皮肤黑色素瘤基于人群的5年净生存率的广泛差异。研究表明女性有生存优势,但原因尚不完全清楚。我们的目的是估计按性别划分的年龄标准化5年净生存率的趋势,并研究年龄、解剖位置和分期对全球女性生存优势的作用。方法:将患者分为5个解剖部位(头颈、躯干、四肢、生殖器官和未指定部位),5个年龄组(15-29岁、30-44岁、45-59岁、60-74岁和75-99岁),并分为二期(非转移与转移)。我们使用非参数Pohar Perme估计值估计净生存率,并在可能的情况下通过年龄、性别、种族/民族和每个国家的日历年校正背景死亡率。根据国际癌症生存标准的权重对所有年龄段的估计进行了标准化。结果:男性一般年龄较大,转移性黑色素瘤的比例高于女性。总体而言,男性最常见的部位是躯干(范围为31% %- 58% %),女性最常见的部位是下肢和臀部(范围为26% %- 40% %)。在2010-2014年期间,所有国家男性的年龄标准化5年净生存率(43 %-92 %)低于女性(54 %-95 %),而且年龄越大,男女的5年净生存率都越低。在所有解剖部位和局部疾病中,观察到妇女的生存优势。结论:女性有更有利的主要预后因素分布,任何预后因素的生存率都最高。公共卫生工作应侧重于提高对黑色素瘤早期症状的认识,特别是在东南欧的老年人中,并提高生存率最低的东亚的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Journal of Cancer
European Journal of Cancer 医学-肿瘤学
CiteScore
11.50
自引率
4.80%
发文量
953
审稿时长
23 days
期刊介绍: The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.
期刊最新文献
European Organisation for Research and Treatment of Cancer (EORTC) 2025 Program for Early Career Investigators: Advancing Ideas into Clinical Research Exploring the diversity of rare exocrine pancreatic cancers: A histo-molecular mapping of a French tertiary-centre cohort Income, treatment patterns and outcome in patients with stage IV colorectal cancer Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial Colon cancer with a peritumoural abscess: Real-world evidence on prognostic and therapeutic implications of a disregarded entity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1